Dose Insider / Glossary / AMPLITUDE-O

AMPLITUDE-OThe heart and kidney trial of efpeglenatide

Updated November 20, 2026 · 3 min read · Gerstein et al., N Engl J Med 2021

AMPLITUDE-O is the cardiovascular and kidney trial of efpeglenatide, a once-weekly GLP-1 medicine. It enrolled 4,076 adults with type 2 diabetes and either cardiovascular disease or kidney disease plus another risk factor, and followed them for a median of 1.81 years. Major cardiovascular events occurred in 7.0% on efpeglenatide against 9.2% on placebo, and a kidney outcome in 13.0% against 18.4%.

13.0%Kidney outcome, Efpeglenatide, events over a median 1.81 years
Events over a median 1.81 yearsAMPLITUDE-O, % of participantsMAJOR HEART EVENTSEfpeglenatide7.0%Placebo9.2%KIDNEY OUTCOMEEfpeglenatide13.0%Placebo18.4%Events over a median 1.81yearsAMPLITUDE-O, % of participantsMAJOR HEART EVENTSEfpeglenatide7.0%Placebo9.2%KIDNEY OUTCOMEEfpeglenatide13.0%Placebo18.4%

Hazard ratios 0.73 for heart events and 0.68 for the kidney outcome.

On this page

It was published in the New England Journal of Medicine in 2021.1

How the trial was run

The trial ran at 344 sites in 28 countries and was placebo-controlled, with efpeglenatide injected under the skin once a week. People qualified with type 2 diabetes and either a history of cardiovascular disease or current kidney disease, defined as an estimated glomerular filtration rate of 25.0 to 59.9, plus at least one other cardiovascular risk factor. They were assigned in a 1:1:1 ratio to weekly efpeglenatide 4 mg, 6 mg or placebo: 2,717 people to the drug and 1,359 to placebo.1

One design detail stands out. Assignment was balanced by whether people were taking an SGLT2 inhibitor, another class of diabetes medicines, so the two groups held similar shares of people on it.1

The main outcome was the first major adverse cardiovascular event: non-fatal heart attack, non-fatal stroke, or death from cardiovascular or undetermined causes.1 Counting deaths of undetermined cause as cardiovascular is a cautious choice: it can only add events, never hide them.

What it found

Gerstein et al., 2021.1

In plain numbers

Over a median of 1.81 years, 2.2 fewer people in every 100 had a major heart event on efpeglenatide. For the kidney outcome, which combined a decline in kidney function with heavy protein loss in the urine, the figure was 5.4 fewer in every 100. Those are rough figures we calculated from the published percentages.1 The rates per 100 person-years, 3.9 against 5.3, are the better way to compare with longer trials, because they adjust for how long people were followed.

What it means

The hazard ratio of 0.73 is similar to that of semaglutide in SUSTAIN 6, 0.74, and stronger than those of liraglutide in LEADER, 0.87, and dulaglutide in REWIND, 0.88.2,3,4 The kidney result points the same way as FLOW, the dedicated kidney trial of semaglutide, which found 24% fewer major kidney disease events.5 Together they suggest the heart and kidney benefits are a feature of several medicines in the class, though not all: ELIXA and EXSCEL did not prove benefit.6,7

Efpeglenatide today

We found no label for efpeglenatide on DailyMed on November 20, 2026, so it is not a medicine that can be prescribed from a current U.S. label.8 The trial still matters as evidence for the class, and for people with type 2 diabetes and kidney disease the medicines with current labels include Ozempic, whose label carries a kidney indication based on FLOW.5

Limits

The trial was short, at a median of 1.81 years, which limits what it can show about long-term outcomes such as kidney failure. It was funded by Sanofi. It is registered as NCT03496298.1 Our page on diarrhea on a GLP-1 covers one of the side effects it reported.

Sources

  1. Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes (AMPLITUDE-O). N Engl J Med 2021;385:896-907. Funded by Sanofi; NCT03496298. doi:10.1056/NEJMoa2108269
  2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834-1844. doi:10.1056/NEJMoa1607141
  3. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016;375:311-322. doi:10.1056/NEJMoa1603827
  4. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 2019;394:121-130. doi:10.1016/S0140-6736(19)31149-3
  5. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med 2024;391:109-121. doi:10.1056/NEJMoa2403347
  6. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (ELIXA). N Engl J Med 2015;373:2247-2257. doi:10.1056/NEJMoa1509225
  7. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). N Engl J Med 2017;377:1228-1239. doi:10.1056/NEJMoa1612917
  8. DailyMed, U.S. National Library of Medicine. Search for "efpeglenatide", no results; read November 20, 2026. dailymed.nlm.nih.gov

Related analyses

Log your doses with blood pressure and kidney lab results over time.

Open Dose Insider